A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas

NCT06490757 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Hepatocellular Adenoma

Interventions

DRUG: Baricitinib

Sponsor

Assistance Publique - Hôpitaux de Paris